Osimertinib Plus Chemotherapy Significantly Extends Survival in Advanced EGFRm NSCLC
Osimertinib plus chemotherapy significantly improves overall survival in EGFRm NSCLC, signaling a new standard of care.
Related Articles
EU Approves Belantamab Mafodotin Combinations for Relapsed/Refractory Myeloma
The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with promising efficacy and safety profiles.
Beyond the Breakthroughs: Unmet Needs in Colorectal Cancer Care
Benjamin Schlechter, MD, discusses the unmet needs and treatment gaps for patients with colorectal cancer.
Phase 3 Study Confirms Long-Term Efficacy of Radiation in Breast Cancer
New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer with fewer side effects.
T-DXd Breakthrough Designation Signals New Era for HER2-Positive Metastatic Breast Cancer
FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.
AI and Innovation in Oncology
Arturo Loaiza-Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into oncology.
Luspatercept Misses Primary End Point, Shows Clinically Meaningful Secondary Benefits
Luspatercept shows promise in improving anemia in myelofibrosis patients, despite not meeting primary trial endpoints, highlighting ongoing treatment challenges.
Carboplatin/Paclitaxel to Immunotherapy Combinations: Evolving First-Line Options in Advanced SCAC
Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus retifanlimab as…
FDA Issues CRL for RP1 in Advanced Melanoma
Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete response letter.
Linvoseltamab Plus Carfilzomib Shows Manageable Safety in RRMM
Rajshekhar Chakraborty, MD, discusses the safety and tolerability of linvoseltamab with carfilzomib when used for the treatment of patients with relapsed/refractory multiple myeloma.
Tailoring CLL Treatment with BTK Inhibitors in a Community Setting
During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.